Abstract
Hypochondroplasia is a skeletal dysplasia characterised by poor childhood growth and an inadequate pubertal growth spurt. 31 children with a radiological diagnosis of hypochondroplasia have been treated for up to 3 years with recombinant human growth hormone, mean dose 17.9 U/m2/week as daily subcutaneous injections. Mean pre-treatment height velocity standard deviation score (SDS) was -0.51; this increased to +1.58 after 1 year of treatment. This improvement diminishes over the next 2 years. The effect on final height remains unknown. There was a considerable variation in clinical response within the group treated.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
